Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

MUTUAL PHARMACEUTICAL COMPANY, INC.

MUTUAL PHARMACEUTICAL COMPANY, INC. is a federal contractor, registered under UEI WVKWLHM9PDH6. It has been awarded $820,939 in federal contracts. Primary work spans Surgical Appliance and Supplies Manufacturing and Pharmaceutical Preparation Manufacturing. Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

WVKWLHM9PDH6

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

3

All time

Active

0

Currently performing

Completed

3

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Awards by NAICS
Awards by Agency Over Time
Awards by Place of Performance

Compete with MUTUAL PHARMACEUTICAL COMPANY, INC.

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for MUTUAL PHARMACEUTICAL COMPANY, INC.

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in MUTUAL PHARMACEUTICAL COMPANY, INC.'s top NAICS codes and agencies

NAICS: 325412
New
Federal
6505--Latanoprost Ophthalmic Solution (VA-27-00006027)
Solicitation # 36E79727R0039
The Department of Veterans Affairs is soliciting proposals for the procurement of Latanoprost 0.005% Ophthalmic Solution to ensure an uninterrupted supply for the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. This unrestricted commercial item procurement is structured into two groups, with one award made in the aggregate for either Group I (single bottles) or Group II (single and bulk cartons). The resulting contract will consist of a one-year base period followed by four pre-priced one-year option periods. Distribution will be managed through the VA and DoD Pharmaceutical Prime Vendor Programs, requiring the contractor to deliver supplies to designated distribution centers based on business-to-business agreements. Award will be granted based on the lowest evaluated price among proposals that meet all non-cost acceptability standards. Offerors must provide a unique 11-digit NDC number and adhere to the American Academy of Ophthalmology’s uniform color-coding system for caps and labels. Strict compliance with FDA current Good Manufacturing Practice standards is required, and offerors must certify they possess the necessary NDA, ANDA, or BLA approvals. Additionally, products must meet rigorous barcoding and serialization requirements under the Drug Supply Chain Security Act, including the use of GS-1 data matrix codes. Proposals must be submitted by November 17, 2026, and must include a 0.5% cost recovery fee embedded in the pricing.
Nac Pharmaceuticals (36E797)

POSTED

1 day ago

DEADLINE

in 17 days
View Details
NAICS: 325412
New
Federal
6505--FY27 Lenalidomide BPA
Solicitation # 36C26227Q0083
The Department of Veterans Affairs, through Network Contracting Office 22, has issued this Sources Sought Notice and Request for Information to identify qualified sources for a Health Service Area 5.3 Blanket Purchase Agreement. The government seeks providers capable of supplying Lenalidomide medication in multiple dosage strengths, specifically 2.5mg, 5mg, 10mg, 15mg, 20mg, and 25mg oral capsules. The medication will be delivered to eight participating VA Medical Centers across Arizona, California, and New Mexico. Due to the nature of the medication, the contractor must hold Food and Drug Administration Risk Evaluation and Mitigation Strategy certification to dispense the product and must ensure strict adherence to handling, storage, and temperature control regulations to maintain medication integrity. This is not a formal solicitation, and responses are intended for market research and planning purposes to inform future acquisition decisions. The anticipated period of performance is one year from the date of award, with orders placed on an as-needed basis via approved purchase orders. Interested respondents must provide a comprehensive capabilities statement, business size status relative to NAICS 325412, and details regarding their status as a manufacturer or authorized distributor. Submissions must also address compliance with the Buy American Act, the Non-Manufacturer Rule, and limitations on subcontracting. All responses must be submitted via email to the designated contracting officer by November 12, 2026.
262-NETWORK Contract Office 22 (36C262)

POSTED

1 day ago

DEADLINE

in 12 days
View Details